News

22 Nov 2016
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
ReproCELL announces an entrustment contract with Healios K.K. (headquarters: Minato Ward, Tokyo; president and CEO: Tadanao Kagimoto; hereafter, Healios) for sample testing support of human clinical trials conducted by Healios, as well as the formation of said contract on the same day.
Read more

16 Nov 2016
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
Today, ReproCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system derived from human iPS cells.
Read more

14 Nov 2016
Joint enterprise - Development of Drug Discovery Applications Using Neurons Derived from iPS Cells
Joint Enterprise of Keio University and Juntendo University - Notice regarding inclusion in Relevant Leading Businesses to Receive Assistance in the Special District of Yokohama City for the project of Development of Drug Discovery Applications Using Neurons Derived from iPS Cells
Read more

More >

Testimonals

I am very pleased with our cooperation so far; nice data and very good fit to our internal knowledge of the compounds

Senior Scientist, Top 20 European Pharma

We used Biopta because they are able to provide sensitive and accurate information from a wide range of different types of tissue

CEO, UK Biotech

Biopta's human tissue services have played a critical part in our compound selection and have added considerable value to our lead compound

President & Head of R&D, Canadian Biotech
Live chat by BoldChat